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Background. Survival outcomes for patients with glioblastoma remain poor, particularly for patients with unmethylated O6-meth-
ylguanine-DNA methyltransferase (MGMT) gene promoter. This phase II, randomized, open-label, multicenter trial investigated the
efficacy and safety of 2 dose regimens of the selective integrin inhibitor cilengitide combined with standard chemoradiotherapy in
patients with newly diagnosed glioblastoma and an unmethylated MGMT promoter.
Methods. Overall, 265 patients were randomized (1:1:1) to standard cilengitide (2000 mg 2×/wk; n¼ 88), intensive cilengitide
(2000 mg 5×/wk during wk 126, thereafter 2×/wk; n¼ 88), or a control arm (chemoradiotherapy alone; n¼ 89). Cilengitide
was administered intravenously in combination with daily temozolomide (TMZ) and concomitant radiotherapy (RT; wk 126), fol-
lowed by TMZ maintenance therapy (TMZ/RTTMZ). The primary endpoint was overall survival; secondary endpoints included
progression-free survival, pharmacokinetics, and safety and tolerability.
Results. Median overall survival was 16.3 months in the standard cilengitide arm (hazard ratio [HR], 0.686; 95% CI: 0.484, 0.972;
P¼ .032) and 14.5 months in the intensive cilengitide arm (HR, 0.858; 95% CI: 0.612, 1.204; P¼ .3771) versus 13.4 months in the
control arm. Median progression-free survival assessed per independent review committee was 5.6 months (HR, 0.822; 95% CI:
0.595, 1.134) and 5.9 months (HR, 0.794; 95% CI: 0.575, 1.096) in the standard and intensive cilengitide arms, respectively, versus
4.1 months in the control arm. Cilengitide was well tolerated.
Conclusions. Standard and intensive cilengitide dose regimens were well tolerated in combination with TMZ/RTTMZ. Inconsis-
tent overall survival and progression-free survival outcomes and a limited sample size did not allow firm conclusions regarding
clinical efficacy in this exploratory phase II study.
Keywords: cilengitide, newly diagnosed glioblastoma, randomized phase II study, unmethylated MGMT promoter.
Glioblastoma is the most common high-grade, primary brain
malignancy in adult patients, accounting for 45% of all
malignant brain tumors.1 Glioblastoma is refractory to most
chemotherapy regimens and has a poor prognosis, with a
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5-year survival rate of less than 5%.1,2 Currently, the standard
treatment for newly diagnosed glioblastoma is surgical resec-
tion as far as safely feasible, therapy with the oral alkylating
agent temozolomide (TMZ) with concomitant radiotherapy
(RT), followed by TMZ maintenance therapy (TMZ/RTTMZ).3,4
Despite the clinically meaningful survival benefit established by
the TMZ/RTTMZ regimen, patients with glioblastoma still
have poor survival, with a median survival of only 15 months
and a 2-year mortality rate of over 75%.3
An important predictive factor for the beneficial effect
of TMZ treatment is the methylation status of the O6-
methylguanine-DNA methyltransferase (MGMT) gene promoter.
Patients with tumors in which the MGMT gene is inactivated due
to hypermethylation of the MGMT promoter have enhanced
chemosensitivity and significantly better survival after TMZ
therapy.5 – 7 Conversely, patients with tumors in which the
MGMT gene is not methylated do not seem to benefit as
much from the addition of TMZ to RT. New treatment options
are therefore urgently required, particularly for patients with
an unmethylated MGMT gene promoter.
The integrin family of cell adhesion molecules, which bind to
extracellular ligands via an arginine-glycine-aspartate (RGD)
domain,8 have been shown to have an important and complex
influence on tumor cell survival, proliferation, migration and in-
vasion, and angiogenesis.9 The integrin subtypes avb3 and
avb5 are widely expressed by both glioblastoma cells and en-
dothelial cells in tumor-associated vasculature.10 Cilengitide
(EMD 121974) is a cyclic peptide with an RGD-binding domain
that selectively and competitively inhibits avb3 and avb5 integ-
rins; it potentially blocks integrin-mediated angiogenesis and
tumor migration while enhancing neoplastic apoptosis.8
Phase I/II studies have previously reported that cilengitide is
well tolerated with antitumor activity in patients with recurrent
or newly diagnosed glioblastoma.11 – 15 Promising antitumor
activity has been reported in phase II studies of cilengitide
administered as a single agent to patients with recurrent glio-
blastoma, with greater responses at higher doses.12,15 In com-
bination with TMZ/RTTMZ in patients with newly diagnosed
glioblastoma, improved overall survival (OS) at higher doses
(2000 mg compared with 500 mg twice weekly) was ob-
served,14 and cilengitide was reported to improve progression-
free survival (PFS) and OS outcomes compared with historical
cohorts treated with standard therapy alone.13
Subsequently, the effects of cilengitide plus TMZ/RTTMZ
were investigated in newly diagnosed glioblastoma patients
with methylated MGMT gene promoter in the randomized, con-
trolled, multicenter, phase III CENTRIC trial.16 Herein, the re-
sults of the open-label, multicenter, randomized controlled
phase II CORE trial are reported, the companion trial of CENTRIC
carried out to evaluate the efficacy and safety of 2 different cil-
engitide regimens in combination with standard TMZ/RTTMZ
in patients with newly diagnosed glioblastoma and unmethy-
lated MGMT gene promoter.
Patients and Methods
Patient Eligibility
Eligible patients had newly diagnosed and histologically con-
firmed supratentorial glioblastoma (World Health Organization
grade IV) with unmethylated MGMT gene promoter status (as-
sessed as previously described16). Diagnosis of glioblastoma
was based on neurosurgical resection of the tumor or on open
biopsy, confirmed by central pathology review. Patients were
stratified according to classifications by recursive partitioning
analysis (RPA; Table 1). Additional inclusion criteria were: age
≥18 years; gadolinium-enhanced MRI,48 h after surgery or be-
fore randomization; stable or decreasing dose of steroids for ≥5
Table 1. Patient baseline characteristics and demographics (intention-to-treat population)
Standard Cilengitide Arm (n¼ 88) Intensive Cilengitide Arm (n¼ 88) Control Arm (n¼ 89)
Age, y
Median (range) 55.6 (26–77) 56.0 (21–76) 57.7 (21–74)
Gender, n (%)
Male 50 (56.8) 50 (56.8) 55 (61.8)
ECOG performance status, n (%)
0 45 (51.1) 46 (52.3) 40 (44.9)
1 42 (47.7) 41 (46.6) 49 (55.1)
Missing 1 (1.1) 1 (1.1) 0 (0.0)
RPA class, n (%)
III 13 (14.8) 15 (17.0) 15 (16.9)
IV 48 (54.5) 49 (55.7) 57 (64.0)
V 26 (29.5) 22 (25.0) 17 (19.1)
Missing 1 (1.1) 2 (2.3) 0 (0.0)
Extent of surgery, n (%)
Total resection 44 (50.0) 46 (52.3) 46 (51.7)
Partial resection 37 (42.0) 37 (42.0) 37 (41.6)
Biopsy 7 (8.0) 4 (4.5) 6 (6.7)
Missing 0 (0.0) 1 (1.1) 0 (0.0)
Time, wk, from diagnosis to randomization, n (%)
Median (range) 4.3 (2.1–6.6) 4.0 (2.1–7.1) 3.7 (1.6–6.7)
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days before randomization; an Eastern Cooperative Oncology
Group (ECOG) performance status of 0–1; satisfactory laboratory
blood and biochemical results within 2 weeks prior to randomi-
zation (absolute neutrophil count .500/mm3, platelets
.100000/mm3; creatinine ,1.5× upper limit of normal [ULN]
or creatinine clearance rate .60 mL/min; prothrombin time in-
ternational normalized ratio within normal limits and partial
thromboplastin time below ULN; hemoglobin .10 g/dL, total
bilirubin ,1.5× ULN; aspartate aminotransferase and alanine
aminotransferase,2.5×ULN [except when attributable to anti-
convulsants or transient increase postsurgery attributable to
narcotics]; and alkaline phosphatase ,2.5× ULN).
The main criteria for exclusion were: prior chemotherapy
within 5 years, RT to the head, systemic antiangiogenic therapy,
a history of malignancy (except for curatively treated cervical
carcinoma in situ or basal cell carcinoma of the skin), and
placement of Gliadel wafer at surgery.
All patients provided informed written consent prior to partic-
ipating in any study procedures or treatments. The study was
conducted in accordance with the Declaration of Helsinki, the In-
ternational Conference on Harmonization note for good clinical
practice (Topic E6, 1996), and applicable regulatory requirements.
The study is registered at clinicaltrials.gov (NCT00813943).
Study Design and Treatment
The randomized phase II study was preceded by a 6-week safe-
ty run-in to determine the tolerability of intensified cilengitide
dosing (2000 mg 3, 4, or 5×/wk) in combination with TMZ/RT.
In the safety run-in, a standard 3+ 3 design was used for step-
wise evaluation of cilengitide dose intensification in 3 patient
cohorts. In each cohort, cilengitide was administered intrave-
nously over 1 h in combination with TMZ/RT standard treatment.
Patients in cohort 1 received 2000 mg cilengitide 3 times week-
ly; patients in cohort 2 received 2000 mg cilengitide 4 times
weekly; and patients in cohort 3 received 2000 mg cilengitide
5 times weekly. Each patient was observed for dose-limiting tox-
icity (DLT) during the first 4 weeks of the combination therapy. If
any of the 3 patients in the first dose cohort experienced a DLT,
an additional 3 patients were added and evaluated in the same
cohort. If 2 or fewer of the 6 patients in the expanded cohort
displayed a DLT, the next dose cohort was evaluated; maximum
tolerated dose (MTD) was considered to be reached if 3 or more
of the 6 patients experienced DLTs.
In the randomized phase II part of the trial, patients were
allocated (1:1:1 ratio) to one of the following treatments: a
standard cilengitide arm of 2000 mg twice weekly, in week
–1 as a single agent, during weeks 1–6 in combination with
TMZ/RT standard therapy, and during weeks 7–34 in combina-
tion with TMZ maintenance therapy; an intensive cilengitide
arm identical to the standard arm except that during the com-
bination with TMZ/RT (wk 1–6), cilengitide 2000 mg was given
5 times a week; and a control arm of the standard regimen of
TMZ/RTTMZ without cilengitide.
For the intensive cilengitide arm in this trial, the frequency of
days cilengitide was administered was increased rather than in-
creasing the dose per day because cilengitide 2000 mg is con-
sidered the maximum safe dose. In addition, the intensive
regimen was administered during weeks 1–6 based on in vivo
preclinical data suggesting that cilengitide had synergy with
radiation therapy.17 Thus, this study was designed for cilengi-
tide intensification during the radiation therapy phase.
During RT, the 1-h cilengitide infusion was recommended to
be administered 4 h before RT based on preclinical modeling
studies.17 The doses and mode of administration of the stan-
dard TMZ/RTTMZ treatment were as previously reported.3
During RT, the TMZ dose was recommended to be administered
1 h before RT. The TMZ maintenance phase consisted of 6
treatment cycles. Patients in the cilengitide treatment arms
received cilengitide for ≥18 months. TMZ was administered
for a total of 34 weeks. Treatment was stopped earlier if
patients developed progressive disease (PD) or unacceptable
toxicity or withdrew from the study for any other reason.
Objectives and Outcome Measures
The primary objective of the safety run-in was to evaluate the
safety and tolerability of stepwise intensified cilengitide in com-
bination with TMZ/RT. In the randomized phase II study, the pri-
mary objective was to determine OS in patients treated with
either standard or intensified cilengitide regimens in combina-
tion with TMZ/RTTMZ, compared with TMZ/RTTMZ alone.
Secondary objectives of the randomized part included PFS,
the pharmacokinetic (PK) profile of the intensive cilengitide reg-
imen (2000 mg 5 d/wk) in combination with TMZ/RTTMZ, and
the safety profile of cilengitide plus TMZ/RTTMZ in the overall
study population.
Response assessment during study therapy was based on
investigator evaluation using Macdonald criteria18; however,
response assessment was also determined centrally by an in-
dependent review committee (IRC) using the Response Assess-
ment in Neuro-Oncology criteria,19 which included blinded MRI
readings, assessment of neurologic status, ECOG scores, and
steroid use. Adverse events (AEs) were coded according to
the Medical Dictionary for Regulatory Activities and their
severity graded according to the National Cancer Institute’s
Common Terminology Criteria for Adverse Events version 3.0.
For cilengitide PK, blood samples on day 1 and day 5 were
taken pre-dose (0 h) and at 1 h, 2 h, 3 h, 4 h, 8 h, and 24 h
after the start of cilengitide infusion. The parameters measured
included maximum plasma concentration as observed (Cmax),
area under the plasma concentration-time curve from zero to
last sampling time (AUC02t), plasma concentration at the end
of infusion (EOI) as observed, apparent terminal half-life (t1/2),
clearance (CL), apparent volume of distribution during the ter-
minal phase, and apparent volume of distribution at steady
state (Vss).
Statistical Analyses
All efficacy analyses were carried out on the intention-to-treat
population, and safety analyses were performed on the safety
population, defined as patients who received any study treat-
ment. Patient characteristics and safety variables were sum-
marized using descriptive statistics. Efficacy outcomes were
evaluated using Kaplan–Meier methodology. OS was measured
from randomization to death; PFS was determined from ran-
domization to the first sign of PD or death due to any cause.
Hazard ratios (HRs), including 95% confidence intervals (CIs),
for both cilengitide arms versus the control arm were
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calculated using a Cox’ proportional hazards model stratified by
patient RPA classification. No confirmatory hypothesis testing
was planned for this phase II study and no adjustment for mul-
tiple testing was performed. Cilengitide PK parameters were
analyzed using standard descriptive statistics; a noncompart-
mental analysis was performed using data from a subset of
11 subjects in the intensive cilengitide regimen after single
(day 1) and repeated dosing (day 5) in week 1 of the study.
Results
Patient Characteristics
Patients were first enrolled for the safety run-in part of the trial
on March 6, 2009, and the cutoff date for the primary analysis
was February 7, 2013. Twelve patients were enrolled in the
safety run-in phase; in the randomized part, a total of 265 pa-
tients were enrolled and allocated to either the standard cilen-
gitide arm (n¼ 88), the intensive cilengitide arm (n¼ 88), or the
control arm (n¼ 89) (Fig. 1). Of these, 89 patients received
standard cilengitide plus TMZ/RTTMZ (including 3 patients
who were randomized to cilengitide intensive treatment but
received cilengitide standard treatment), 81 patients received
intensive cilengitide plus TMZ/RTTMZ, and 85 patients were
treated in the control arm. Patient baseline characteristics
and demographics were similar across treatment arms and
are summarized in Table 1. All patients underwent histology
review: 94.7% of patients had glioblastoma, 3.8% of patients
had gliosarcoma, and 1.1% of patients had a giant-cell
glioblastoma.
In total, 252 patients (95.0%) discontinued treatment. PD
was the most common reason for discontinuation: 62 patients
(70.0%) in the standard cilengitide arm, 65 patients (73.9%) in
the intensive cilengitide arm, and 61 patients (68.5%) in the
control arm (Fig. 1). Overall, 165 patients (62.3%) received an-
ticancer follow-up therapy. The most frequent follow-up treat-
ments were cytotoxic chemotherapy for 119 patients, surgery
for 47 patients, and treatment targeting pathways of vascular
endothelial growth factor for 39 patients. Of the patients re-
ceiving follow-up antineoplastic agents, 29.5% in the standard
cilengitide arm, 33% in the intensive cilengitide arm, and 22.5%
in the control arm received bevacizumab.
Safety of Intensive Cilengitide Dosing (Safety Run-in)
Twelve patients completed the safety run-in; no MTD for cilen-
gitide was identified. No DLTs were observed in cohorts 1 and 2;
1 patient experienced a DLT of hyperbilirubinemia in cohort
3. This cohort was then expanded to 6 patients. No further
DLTs were observed. Four serious AEs considered related to
cilengitide were observed in 2 patients (hyperbilirubinemia,
elevated alanine aminotransferase, and elevated aspartate
aminotransferase in 1 patient; and pulmonary embolism in an-
other). No AEs leading to death were reported during the safety
run-in. The overall safety profile observed in this safety run-in
was consistent with the underlying malignancy of the patients
and/or reflected AEs associated with the TMZ/RTTMZ regi-
men. The safety monitoring committee recommended cilengi-
tide 2000 mg administered 5 times weekly for evaluation as
intensive regimen in the randomized part of the CORE study.
Fig. 1. CONSORT diagram. aIncludes 3 patients who were randomized to cilengitide intensive (CIL int) treatment but actually received cilengitide
standard treatment.
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Treatment Exposure (Randomized Study)
Patients in the intensive cilengitide arm received cilengitide for
a median of 34.3 weeks compared with a median of 28.3 weeks
for patients in the standard cilengitide arm. Similarly, patients
in the intensive cilengitide arm received TMZ for a median of
34.0 weeks compared with a median duration of 28.0 weeks
in the standard cilengitide arm. In the control arm, TMZ was
administered for a median of 30.0 weeks.
Overall Survival
The median OS was 13.4 months (range, 0–30 mo) in the con-
trol arm, 16.3 months (range, 0–29) in the standard cilengitide
arm, and 14.5 months (range, 0–29) in the intensive cilengitide
arm (Fig. 2). The HR (stratified for RPA classes III/IV–V) in the
standard cilengitide arm versus the control arm was 0.686
(95% CI: 0.484, 0.972; P¼ .0328). The HR (stratified for RPA
classes III/IV–V) for the intensive cilengitide versus the control
arm was 0.858 (95% CI: 0.612, 1.204; P¼ .3771). Forest plots of
OS in the standard cilengitide versus control and the intensive
cilengitide versus control arms according to patient baseline
characteristics are provided in Supplementary Fig. S1.
Progression-Free Survival
Based on the IRC assessment, median PFS was 4.1 months
(range, 0–26) in the control arm, 5.6 months (range, 0–27)
in the standard cilengitide arm, and 5.9 months (range, 0–
28) in the intensive cilengitide arm (Fig. 3A). The HR (stratified
for RPA classes III/IV–V) for the standard cilengitide versus the
control arm was 0.822 (95% CI: 0.595, 1.134); for the intensive
cilengitide versus control arm the HR (stratified for RPA classes
III/IV–V) was 0.794 (95% CI: 0.575, 1.096). Forest plots illus-
trating the PFS per IRC assessment in the standard cilengitide
versus control and the intensive cilengitide versus control
arms based on patient baseline characteristics are provided in
Supplementary Fig. S2.
The median PFS as assessed by investigators was 6.0
months (range, 0–26) in the control arm, 6.4 months (range,
0– 27) in the standard cilengitide arm, and 7.5 months
(range, 0–28) in the intensive cilengitide arm (Fig. 3B). The HR
(stratified for RPA classes III/IV–V) for the standard cilengitide
versus the control arm was 0.772 (95% CI: 0.559, 1.066). For
the comparison of the intensive cilengitide versus the control
arm the HR (stratified for RPA classes III/IV –V) was 0.720
(95% CI: 0.521, 0.995). Forest plots describing investigator as-
sessed PFS in the standard cilengitide versus control and the in-
tensive cilengitide versus control arms according to patient
baseline characteristics are shown in Supplementary Fig. S3.
Pharmacokinetic Profile
On day 1, after a single dose, exposure to cilengitide as defined
by AUC02t was 259 526 h*ng/mL (geometric mean). The Cmax
of 105 336 ng/mL (geometric mean) was reached a median
of 1.02 h after the start of cilengitide infusion in concordance
with the EOI. The median t1/2 was 2.00 h and the geometric
mean CL was 122.28 mL/min. The geometric mean volume of
distribution was 23.98 L. On day 5 (after 5 repeated doses of
cilengitide), exposure to cilengitide was 297 961 h*ng/mL
Fig. 2. Kaplan–Meier estimate for OS in the 3 treatment arms of the CORE phase II study. CIL, cilengitide; int, intensive.
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Fig. 3. Kaplan–Meier estimate for PFS assessed (A) by IRC and (B) by investigators. CIL, cilengitide; int, intensive.
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(geometric mean AUC02t). The Cmax of 128 670 ng/mL (geo-
metric mean) was reached a median of 1.02 h after the start
of cilengitide infusion, again in concordance with the EOI.
The median t1/2 was 2.35 h and the geometric mean CL
was 104.15 mL/min. The Vss (geometric mean) was 17.39
L. Cilengitide did not accumulate after 5 daily infusions of
cilengitide 2000 mg daily, most likely as a consequence of
the short t1/2 of the drug. Overall, the observed exposure to
cilengitide in patients in this study was comparable to that
observed for cilengitide in previous clinical studies in glioblastoma
patients.11 – 13
Safety
Treatment-emergent adverse events (TEAEs) occurred in 82 pa-
tients (96.5%) in the control arm, 88 patients (98.9%) in the
standard cilengitide arm, and 80 patients (98.8%) in the inten-
sive cilengitide arm (Table 2). The most commonly observed
TEAEs are listed in Table 3. Serious TEAEs were reported in 30 pa-
tients (35.3%) in the control arm, 47 patients (52.8%) in the
standard cilengitide arm, and 36 patients (44.4%) in the
intensive cilengitide arm. Death due to a TEAE occurred in 5 pa-
tients (5.9%) in the control arm, 8 patients (9.0%) in the stan-
dard cilengitide arm, and 8 patients (9.9%) in the intensive
cilengitide arm. Of these, 5 deaths were considered as related
to study treatment (cilengitide, TMZ, or RT): 2 cases of pancyto-
penia (1 patient each in the intensive cilengitide and control
arms), 1 case of thrombocytopenia in the standard cilengitide
arm, and 2 cases of pulmonary embolism (1 patient in each of
the 2 cilengitide-containing treatment arms).
Discussion
The CORE trial was conducted to investigate the safety and ef-
ficacy of standard and intensive cilengitide dosing in combina-
tion with TMZ/RTTMZ in patients with newly diagnosed
glioblastoma and an unmethylated MGMT gene promoter.
Prior to the actual phase II part of the trial, a safety run-in
was performed because of the lack of prior clinical experience
with 3, 4, or 5 times weekly intensive cilengitide dosing as a
single agent or in combination regimens for glioblastoma treat-
ment. The safety run-in did not identify an MTD and demon-
strated that the intensive regimen of cilengitide 2000 mg
administered 5 times weekly was well tolerated and suitable
for further investigation.
The primary objective of the randomized phase II trial was
OS in the cilengitide treatment arms compared with the control
arm that received standard TMZ/RTTMZ alone. There were no
major imbalances in prognostic factors between the treatment
arms in this study. Median OS was increased in both the stan-
dard twice-weekly and in the intensive 5-times-weekly cilengi-
tide treatment arms, compared with the control arm. However,
in contrast to the synergy between cilengitide and RT previously
demonstrated in orthotopic in vivo models of glioblastoma,17
the observed increase in OS was more pronounced in the stan-
dard cilengitide arm compared with the intensive cilengitide
arm. Conversely, the observed increase in median PFS over
the control arm, as assessed by both the IRC and investigator,
was greater in the intensive cilengitide arm compared with the
standard cilengitide arm. These contradictory results may, in
part, be related to compartmental expression of the target
integrins by proliferating endothelial cells or tumor cells,
which can enable cilengitide to have antiangiogenic and antitu-
mor effects. The paradox that with standard-dose cilengitide a
greater improvement in OS was observed than with the inten-
sive dose can currently not be explained. Of note, the median
OS and PFS observed for the control arm of the CORE study were
similar to those previously reported for patients with newly di-
agnosed glioblastoma and unmethylated MGMT promoter
treated with TMZ/RTTMZ.6 The determination of progression
remains a challenge in the postradiation glioblastoma popula-
tion, and this may have contributed to observed inconsistencies
for this endpoint. Further questions about the relative efficacy
of the treatment arms were raised by the late separation of
the OS curves, which did not diverge in the 3 different treat-
ment arms until 1 year postrandomization. The significance
of this observation is unclear. However, a possible explanation
could be that tumor molecular heterogeneity resulted in a sub-
set of patients having a survival advantage due to tumors that
may be more dependent on integrin signaling.
The multicenter, randomized, open-label, phase III
companion study CENTRIC investigated efficacy and safety of
twice-weekly infusions of 2000 mg cilengitide added to TMZ/
RTTMZ in the complementary population of patients with
newly diagnosed glioblastoma and methylated MGMT gene
promoter.16 Independent of treatment, MGMT promoter meth-
ylation has been shown to be a favorable prognostic factor, as-
sociated with an OS of 18.2 months, compared with 12.2
months for patients with unmethylated MGMT promoter status
(P, .001).6 In the CENTRIC study, the addition of cilengitide to
standard TMZ/RTTMZ treatment failed to prolong OS (26 mo
Table 2. Treatment-emergent adverse events (safety population)
Standard
Cilengitide
Arm
(n¼ 89a)
Intensive
Cilengitide
Arm
(n¼ 81)
Control
Arm
(n¼ 85)
TEAEs, n (%)
All 88 (98.9) 80 (98.8) 82 (96.5)
Study treatmentb–related 70 (78.7) 64 (79.0) 56 (65.9)
Serious TEAEs, n (%)
All 47 (52.8) 36 (44.4) 30 (35.3)
Study treatment*–related 13 (14.6) 4 (4.9) 5 (5.9)
NCI-CTCAE grade 3 or 4 TEAEs, n (%)
All 57 (64.0) 47 (58.0) 45 (52.9)
Study treatmentb–related 25 (28.1) 19 (23.5) 17 (20.0)
TEAEs leading to death, n (%)
All 8 (9.0) 8 (9.9) 5 (5.9)
Study treatmentb–related 2 (2.2) 2 (2.5) 1 (1.2)
Abbreviation: NCI-CTCAE, National Cancer Institute’s Common
Terminology Criteria for Adverse Events.
aIncludes 3 patients who were randomized to cilengitide intensive
treatment but actually received cilengitide standard treatment; they
were therefore allocated to the cilengitide standard treatment group
for the safety population.
bCilengitide, radiotherapy, or temozolomide.
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Table 3. Most common TEAEsa by system organ class and preferred term (safety population)
System Organ Class Standard Cilengitide Arm
(n¼ 89b)
Intensive Cilengitide Arm
(n¼ 81)
Control Arm (n¼ 85)
Preferred Term, n (%) Any Grade Grade ≥3 Any Grade Grade ≥3 Any Grade Grade ≥3
Blood and lymphatic system disorders 27 (30.3) 13 (14.6) 31 (38.3) 14 (17.3) 28 (32.9) 11 (12.9)
Anemia 6 (6.7) 3 (3.4) 9 (11.1) 1 (1.2) 1 (1.2) 1 (1.2)
Lymphopenia 9 (10.1) 6 (6.7) 7 (8.6) 2 (2.5) 7 (8.2) 5 (5.9)
Neutropenia 12 (13.5) 5 (5.6) 10 (12.3) 1 (1.2) 8 (9.4) 2 (2.4)
Thrombocytopenia 11 (12.4) 4 (4.5) 15 (18.5) 9 (11.1) 17 (20.0) 7 (8.2)
Gastrointestinal disorders 56 (62.9) 3 (3.4) 52 (64.2) 3 (3.7) 51 (60.0) 2 (2.4)
Constipation 26 (29.2) 0 (0.0) 27 (33.3) 1 (1.2) 27 (31.8) 0 (0.0)
Diarrhea 9 (10.1) 0 (0.0) 6 (7.4) 1 (1.2) 2 (2.4) 0 (0.0)
Nausea 33 (37.1) 1 (1.1) 31 (38.3) 1 (1.2) 30 (35.3) 1 (1.2)
Vomiting 19 (21.3) 1 (1.1) 18 (22.2) 1 (1.2) 21 (24.7) 2 (2.4)
General disorders and administration site conditions 66 (74.2) 13 (14.6) 57 (70.4) 9 (11.1) 42 (49.4) 10 (11.8)
Asthenia 22 (24.7) 2 (2.2) 25 (30.9) 4 (4.9) 12 (14.1) 3 (3.5)
Fatigue 28 (31.5) 5 (5.6) 21 (25.9) 2 (2.5) 21 (24.7) 4 (4.7)
Gait disturbance 3 (3.4) 0 (0.0) 7 (8.6) 0 (0.0) 11 (12.9) 2 (2.4)
Peripheral edema 9 (10.1) 1 (1.1) 5 (6.2) 0 (0.0) 8 (9.4) 0 (0.0)
Pyrexia 17 (19.1) 0 (0.0) 14 (17.3) 0 (0.0) 11 (12.9) 1 (1.2)
Infections and infestations 43 (48.3) 6 (6.7) 42 (51.9) 2 (2.5) 25 (29.4) 2 (2.4)
Nasopharyngitis 10 (11.2) 1 (1.1) 5 (6.2) 0 (0.0) 1 (1.2) 0 (0.0)
Upper respiratory tract infection 6 (6.7) 0 (0.0) 10 (12.3) 0 (0.0) 5 (5.9) 0 (0.0)
Urinary tract infection 6 (6.7) 0 (0.0) 10 (12.3) 0 (0.0) 6 (7.1) 0 (0.0)
Injury, poisoning, and procedural complications 24 (27.0) 2 (2.2) 16 (19.8) 1 (1.2) 16 (18.8) 0 (0.0)
Radiation skin injury 11 (12.4) 0 (0.0) 3 (3.7) 0 (0.0) 3 (3.5) 0 (0.0)
Investigations 18 (20.2) 7 (7.8) 23 (28.4) 5 (6.2) 21 (24.7) 9 (10.6)
Platelet count decreased 3 (3.4) 2 (2.2) 1 (1.2) 0 (0.0) 5 (5.9) 4 (4.8)
Metabolism and nutrition disorders 31 (34.8) 5 (5.6) 31 (38.3) 7 (8.6) 26 (30.6) 3 (3.5)
Decreased appetite 21 (23.6) 1 (1.1) 18 (22.2) 0 (0.0) 18 (21.2) 1 (1.2)
Musculoskeletal and connective tissue disorders 33 (37.1) 4 (4.5) 36 (44.4) 1 (1.2) 16 (18.8) 2 (2.4)
Muscular weakness 10 (11.2) 3 (3.4) 19 (23.5) 1 (1.2) 4 (4.7) 1 (1.2)
Pain in extremity 9 (10.1) 1 (1.1) 3 (3.7) 0 (0.0) 6 (7.1) 0 (0.0)
Nervous system disorders 67 (75.3) 26 (29.2) 54 (66.7) 27 (33.3) 54 (63.5) 20 (23.5)
Convulsion 13 (14.6) 5 (5.6) 14 (17.3) 6 (7.4) 12 (14.1) 5 (5.9)
Epilepsy 6 (6.7) 4 (4.5) 4 (4.9) 2 (2.5) 2 (2.4) 1 (1.2)
Headache 39 (43.8) 4 (4.5) 33 (40.7) 4 (4.9) 28 (32.9) 4 (4.7)
Hemiparesis 8 (9.0) 5 (5.6) 7 (8.6) 5 (6.2) 9 (10.6) 6 (7.1)
Neurologic status worsening 0 (0.0) 0 (0.0) 6 (7.4) 5 (6.2) 0 (0.0) 0 (0.0)
Psychiatric disorders 32 (36.0) 3 (3.4) 33 (40.7) 1 (1.2) 24 (28.2) 2 (2.4)
Depression 12 (13.5) 0 (0.0) 9 (11.1) 0 (0.0) 2 (2.4) 0 (0.0)
Insomnia 12 (13.5) 0 (0.0) 15 (18.5) 0 (0.0) 12 (14.1) 1 (1.2)
Respiratory, thoracic, and mediastinal disorders 23 (25.8) 13 (14.6) 18 (22.2) 4 (4.9) 18 (21.2) 3 (3.6)
Cough 9 (10.1) 1 (1.1) 7 (8.6) 0 (0.0) 3 (3.5) 0 (0.0)
Pulmonary embolism 10 (11.2) 10 (11.2) 2 (2.5) 2 (2.5) 1 (1.2) 1 (1.2)
Skin and subcutaneous tissue disorders 44 (49.4) 3 (3.4) 39 (48.1) 2 (2.5) 26 (30.6) 0 (0.0)
Alopecia 14 (15.7) 0 (0.0) 18 (22.2) 2 (2.5) 11 (12.9) 0 (0.0)
Pruritus 9 (10.1) 0 (0.0) 11 (13.6) 0 (0.0) 5 (5.9) 0 (0.0)
Rash 11 (12.4) 1 (1.1) 8 (9.9) 0 (0.0) 3 (3.5) 0 (0.0)
Vascular disorders 19 (21.3) 12 (13.5) 17 (21.0) 4 (4.9) 13 (15.3) 4 (4.7)
Deep vein thrombosis 7 (7.9) 7 (7.9) 2 (2.5) 2 (2.5) 4 (4.7) 3 (3.5)
aIn either treatment arm ≥10% TEAE of any grade or ≥4% TEAE of grade 3.
bIncludes 3 patients who were randomized to cilengitide intensive treatment but actually received cilengitide standard treatment; they were there-
fore allocated to the cilengitide standard treatment group for the safety population.
Nabors et al.: Cilengitide in newly diagnosed glioblastoma: CORE study
Neuro-Oncology 715
in both cilengitide and control arms; HR¼ 1.02, P¼ .86), and
only a slight increase in PFS was observed in the cilengitide
versus the control arm (13.5 vs 10.7 mo, HR 0.93, P¼ .48).16
The limited efficacy benefit observed in the CORE trial to-
gether with the negative outcomes of CENTRIC suggest that
the addition of cilengitide as administered in these studies
does not improve outcome when added to TMZ/RTTMZ for
newly diagnosed glioblastoma patients. In addition, due to
the relatively small sample size, CORE was not powered to
detect statistically significant differences between the cilengi-
tide treatment arms compared with the control arm in terms
of the efficacy outcomes.
The PK analysis revealed a PK profile in line with previously
reported PK analyses of cilengitide12,13 characterized by a
short elimination half-life, leading to a lack of accumulation
after repeated dosing. However, the short half-life may mean
that constant infusion is required or a modification in the
drug structure/formulation may be needed. Maximum plasma
concentrations were reached shortly after the end of treatment
infusion, as in previous studies.12,13 In the current study, both
cilengitide regimens (standard and intensive) were well tolerat-
ed and no new safety concerns for cilengitide administered in
combination with TMZ/RTTMZ were observed. The incidence
of pulmonary embolism was higher in the cilengitide arms in
this trial. Thromboembolic events associated with cilengitide
have also been reported in previous cilengitide studies,11,14,16
although in another phase I/II cilengitide study the incidence
did not appear to increase following the addition of cilengi-
tide.13 Overall, the AE profile observed in the cilengitide treat-
ment arms was as expected for patients with glioblastoma
and similar to that previously reported in clinical trials of
cilengitide.11 – 13,16
In conclusion, the addition of either standard regimen of
twice-weekly 2000 mg/d infusions of cilengitide or an intensi-
fied regimen of 2000 mg/d 5 times per week to the standard
of care with TMZ/RTTMZ was well tolerated in patients with
newly diagnosed glioblastoma with an unmethylated MGMT
gene promoter. However, modest improvement in OS and PFS
outcomes between the cilengitide arms of this exploratory
phase II study together with the negative efficacy outcome
of cilengitide in the phase III CENTRIC trial16 indicate that cilen-
gitide as dosed in these studies is ineffective when added to
TMZ/RTTMZ for newly diagnosed glioblastoma patients. Fur-
ther clinical investigations may be warranted if a potentially
predictive biomarker of response to cilengitide is identified,
such as avb3 and avb5 expression on tumor tissue or prolifer-
ating endothelial cells. Although results of the CORE and CEN-
TRIC trials are disappointing, integrins are critically involved in
several facets of glioblastoma biology and thus remain attrac-
tive therapeutic targets.
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